DrugDashboards

neffy

epinephrine · EPINEPHRINE 1 mg/100uL · Spray · Nasal · Sportpharm LLC

NDC 85766-0129-02 · 2 BLISTER PACK in 1 CARTON / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK / 100 uL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 82580-0010-02) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$384.00per unit
middle half $381.49$384.00 · 48 plans · Apr 1, 2026
Est. net of rebates
$230.40–$288.00
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
1%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 44%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 4 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for epinephrine (other) in the next 90 days

sole-source market · price up 6% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA214697
TE code
Approval date
Aug 9, 2024
Patents / exclusivity
16 patents, 0 exclusivities
TypeNumber / codeExpires
patent11918655Feb 6, 2039
patent11744895Feb 6, 2039
patent11717571Feb 6, 2039
patent11191838Feb 6, 2039
patent11191838Feb 6, 2039
patent10682414Feb 6, 2039
patent12324838Feb 6, 2039
patent12324838Feb 6, 2039
patent10682414Feb 6, 2039
patent11918655Feb 6, 2039
patent11744895Feb 6, 2039
patent11717571Feb 6, 2039

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of epinephrine (Spray)

LabelerStrengthFirst seenLast seen
ARS Pharmaceuticals Operations, Inc.EPINEPHRINE 1 mg/100uLJul 15, 2026Sep 2, 2026
ARS Pharmaceuticals Operations, Inc.EPINEPHRINE 2 mg/100uLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCEPINEPHRINE 2 mg/100uLJul 15, 2026Sep 2, 2026
Sportpharm LLCEPINEPHRINE 1 mg/100uLJul 15, 2026Sep 2, 2026
Sportpharm LLCEPINEPHRINE 2 mg/100uLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "neffy — NDC 85766-0129-02," retrieved September 3, 2026, https://drugdashboards.com/drug/85766012902.

Free to cite with attribution — see how the data is put together.